Stock Analiz

PDS Biotechnology Corp PDSB

Biotechnology: Pharmaceutical Preparations · IPO 2015 · data as of November 13, 2026

$0.87Market cap $107M
Open the interactive analysis →

PDS Biotechnology Corp (PDSB) is a healthcare company listed in the US with a market value of about $107M.

Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (3/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -90%.

About PDS Biotechnology

PDS Biotechnology is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2015. It was profitable in 0 of the last 10 years in our data. Its share count rose by 62% over three years (dilution for shareholders).

Score: 0.6 / 5

Value0/5
Future growth0/5
Track record0/5
Financial health3/5
Shareholder returns0/5

Checks passed

  • More cash than debt, or low debt to equity
  • Interest covered more than 5 times
  • Debt below 3 years of free cash flow

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S—
P/B—
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-25.9%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)—
ROIC (5-yr avg.)-89.9%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal year2025202420232022202120202019201820172016
Revenue——————————
Net income-$34M-$38M-$43M-$41M-$17M-$15M-$7M-$4M-$51M-$39M
Free cash flow-$28M-$35M-$34M————-$2M-$41M-$33M
EPS (diluted)$-0.74$-1.03$-1.39$-1.43$-0.66$-0.89$-1.44$1.15$-1.67$-1.34
Net margin——————————
ROIC-145.4%-125.8%-91.3%-60.2%-26.6%-53.7%-170.5%—-255.0%-36.2%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 2 analysts is $4.50, 416% above the current price; targets range from $4.00 to $5.00; the consensus rating is “Strong buy”; expected EPS is $-0.44 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does PDS Biotechnology pay a dividend?

Not currently.

Is PDS Biotechnology a good stock to buy?

We do not give buy or sell advice. PDS Biotechnology scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.